Publications

Soft Tissue Metrics in Thyroid Eye Disease: An International Thyroid Eye Disease Society Reliability Study.

Mawn LA, Dolman PJ, Kazim M, Strianese D, Genol I, Chong KKL, Sullivan TJ, Korn BS, Naik M, Dutton J, Velasco E Cruz A, Li C.

Ophthalmic Plast Reconstr Surg. 2018 Feb 16.

Axial Globe Position Measurement: A Prospective Multicenter Study by the International Thyroid Eye Disease Society.

Bingham CM, Sivak-Callcott JA, Gurka MJ, Nguyen J, Hogg JP, Feldon SE, Fay A, Seah LL, Strianese D, Durairaj VD, Uddin J, Devoto MH, Harris M, Saunders J, Osaki TH, Looi A, Teo L, Davies BW, Elefante A, Shen S, Realini T, Fischer W, Kazim M.

Ophthalmic Plast Reconstr Surg. 2016 Mar-Apr;32(2):106-12.

Reliability of estimating ductions in thyroid eye disease: an International Thyroid Eye Disease Society multicenter study.

Dolman PJ, Cahill K, Czyz CN, Douglas RS, Elner VM, Feldon S, Kazim M, Lucarelli M, Sivak-Collcott J, Stacey AW, Strianese D, Uddin J.

Ophthalmology. 2012 Feb;119(2):382-9.

Development of criteria for evaluating clinical response in thyroid eye disease using a modified Delphi technique.

Douglas RS, Tsirbas A, Gordon M, Lee D, Khadavi N, Garneau HC, Goldberg RA, Cahill K, Dolman PJ, Elner V, Feldon S, Lucarelli M, Uddin J, Kazim M, Smith TJ, Khanna D; International Thyroid Eye Disease Society.

Arch Ophthalmol. 2009 Sep;127(9):1155-60.

Teprotumumab for the Treatment of Active Thyroid Eye Disease.

Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, Fleming JC, Fowler BT, Marcocci C, Marinò M, Antonelli A, Dailey R, Harris GJ, Eckstein A, Schiffman J, Tang R, Nelson C, Salvi M, Wester S, Sherman JW, Vescio T, Holt RJ, Smith TJ.

N Engl J Med. 2020 Jan 23;382(4):341-352.

Graves’ disease.

Davies TF, Andersen S, Latif R, Nagayama Y, Barbesino G, Brito M, Eckstein AK, Stagnaro-Green A, Kahaly GJ.

Nat Rev Dis Primers.2020 Jul 2;6(1):52.

New insights into the pathogenesis and nonsurgical management of Graves orbitopathy.

Taylor PN, Zhang L, Lee RWJ, Muller I, Ezra DG, Dayan CM, Kahaly GJ, Ludgate M.

Nat Rev Endocrinol.2020 Feb;16(2):104-116.

Selenium in thyroid disorders – essential knowledge for clinicians.

Winther KH, Rayman MP, Bonnema SJ, Hegedüs L.

Nat Rev Endocrinol.2020 Mar;16(3):165-176.

A Prospective, Randomized, Double-blind, Placebo-controlled Study of Orbital Radiotherapy for Graves’ Ophthalmopathy.

Gorman CA, Garrity JA, Fatourechi V, Bahn RS, Petersen IA, Stafford SL, Earle JD, Forbes GS, Kline RW, Bergstralh EJ, Offord KP, Rademacher DM, Stanley NM, Bartley GB.

Ophthalmology. 2020 Apr;127(4S):S160-S171.

Graves’ disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy.

Antonelli A, Fallahi P, Elia G, Ragusa F, Paparo SR, Ruffilli I, Patrizio A, Gonnella D, Giusti C, Virili C, Centanni M, Shoenfeld Y, Ferrari SM.

Best Pract Res Clin Endocrinol Metab.2020 Jan;34(1):101388.

TSH/IGF1 receptor crosstalk: Mechanism and clinical implications.

Krieger CC, Neumann S, Gershengorn MC.

Pharmacol Ther. 2020 May;209:107502.

Medical treatment in thyroid eye disease in 2020.

Khong JJ, McNab A.

Br J Ophthalmol. 2021 Mar;105(3):299-305.

Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.

Kahaly GJ, Douglas RS, Holt RJ, Sile S, Smith TJ.

Lancet Diabetes Endocrinol. 2021 Jun;9(6):360-372.

Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies.

Winn BJ, Kersten RC.

Ophthalmology. 2021 Nov;128(11):1627-1651.

Statins for Graves’ orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial.

Lanzolla G, Sabini E, Leo M, Menconi F, Rocchi R, Sframeli A, Piaggi P, Nardi M, Marcocci C, Marinò M.

Lancet Diabetes Endocrinol. 2021 Nov;9(11):733-742.

Therapeutic IGF-I receptor inhibition alters fibrocyte immune phenotype in thyroid-associated ophthalmopathy.

Fernando R, Caldera O, Smith TJ.

Proc Natl Acad Sci USA. 2021 Dec 28;118(52):e2114244118.

The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy.

Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, Marinò M, Vaidya B, Wiersinga WM; EUGOGO †.

Eur J Endocrinol. 2021 Aug 27;185(4):G43-G67.

Modulating gut microbiota in a mouse model of Graves’ orbitopathy and its impact on induced disease.

Moshkelgosha S, Verhasselt HL, Masetti G, Covelli D, Biscarini F, Horstmann M, Daser A, Westendorf AM, Jesenek C, Philipp S, Diaz-Cano S, Banga JP, Michael D, Plummer S, Marchesi JR, Eckstein A, Ludgate M, Berchner-Pfannschmidt U; INDIGO consortium.

Microbiome. 2021 Feb 16;9(1):45.

Systematic review of COVID-19 and autoimmune thyroiditis.

Esra Tutal, Resat Ozaras, Hakan Leblebicioglu.

Travel Med Infect Dis. 2022 May-Jun;47:102314.

Relapsed and newly diagnosed Graves’ disease due to immunization against COVID-19: A case series and review of the literature.

Hayri Bostan, Bekir Ucan, Muhammed Kizilgul, Murat Calapkulu, Sema Hepsen, Umran Gul, Ilknur Ozturk Unsal, Erman Cakal.

J Autoimmun. 2022 Apr;128:102809.

Orbital Radiation for Thyroid Eye Disease: A Report by the American Academy of Ophthalmology.

Rachel K Sobel, Vinay K Aakalu, M Reza Vagefi, Jill A Foster, Jeremiah P Tao, Suzanne K Freitag, Edward J Wladis, Timothy J McCulley, Michael T Yen.

Ophthalmology. 2022 Apr;129(4):450-455.

Current concepts regarding Graves’ orbitopathy.

Luigi Bartalena, Maria Laura Tanda.

J Intern Med. 2022 Nov;292(5):692-716.